atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

  •   Posted on: 2022-11-10
  • |
  •   Views: 413

Oct. 12, 2022

By: Jonathan Block

  • A drug from atai Life Sciences (NASDAQ:ATAI) based on an active component found in the plant kratom led to pain-relieving effects in an early-stage trial.

  • The candidate, KUR-101, is an oral form of deuterated mitragynine, the major active alkaloid found in kratom. It is under investigation for opioid use disorder.

  • Results showed that KUR-101 was safe and well-tolerated with a dose-proportional pharmacokinetic profile.

  • Additional results, including comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, is expected by the end of the year.